{"id":742146,"date":"2011-01-12T07:30:00","date_gmt":"2011-01-12T07:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\/"},"modified":"2026-08-10T13:01:19","modified_gmt":"2026-08-10T17:01:19","slug":"merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\/","title":{"rendered":"Merck and PAREXEL Form Strategic Alliance Focused on Clinical Development of Biosimilar Candidates"},"content":{"rendered":"<p class=\"bwalignc\">       PAREXEL to provide a broad range of regulatory and clinical services        to Merck BioVentures including exclusivity for certain candidates     <\/p>\n<p>\n      Merck (NYSE:MRK) (known outside the United States and Canada as MSD) and<br \/>\n      PAREXEL International Corporation (NASDAQ: PRXL), a leading global<br \/>\n      biopharmaceutical services provider, today announced that they have<br \/>\n      entered into an alliance by which PAREXEL will provide strategic access<br \/>\n      to global clinical development services for designated biosimilar<br \/>\n      candidates to Merck BioVentures. Merck BioVentures, a division of Merck,<br \/>\n      is focused on the delivery of high quality biosimilars to the patients<br \/>\n      that need them.\n    <\/p>\n<p>\n      &#8220;PAREXEL has extensive, industry-leading experience with biosimilar<br \/>\n      development, and we truly understand the scientific complexities, and<br \/>\n      regulatory pathways involved,&#8221; said Josef von Rickenbach, chairman and<br \/>\n      chief executive officer of PAREXEL.<b> <\/b>&#8220;We are committed to working<br \/>\n      with Merck BioVentures to assist in advancing its biosimilar portfolio<br \/>\n      in this rapidly developing market segment for the benefit of patients<br \/>\n      worldwide.<i>&#8220;<\/i>\n    <\/p>\n<p>\n      Under the terms of the agreement, PAREXEL will provide Merck BioVentures<br \/>\n      with strategic access to a broad range of regulatory strategy and<br \/>\n      clinical development planning capabilities for the development of<br \/>\n      certain broad classes of biosimilars across various therapeutic areas,<br \/>\n      including exclusivity for certain candidates. The agreement also<br \/>\n      provides for the establishment of a dedicated Merck BioVentures unit<br \/>\n      within the PAREXEL organization. Further details of the agreement were<br \/>\n      not disclosed.\n    <\/p>\n<p>\n      &#8220;Through this agreement, Merck BioVentures has secured broad strategic<br \/>\n      access to PAREXEL&#8217;s proven biosimilar clinical development experience,&#8221;<br \/>\n      said Michael Kamarck, president of Merck BioVentures. &#8220;This agreement<br \/>\n      positions Merck BioVentures for success with an industry leading partner<br \/>\n      that has the expertise and resources to conduct clinical development of<br \/>\n      our diverse portfolio of candidates to allow timely delivery of products<br \/>\n      to the marketplace.&#8221;\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com&amp;esheet=50281534&amp;lan=en-US&amp;anchor=www.merck.com.&amp;index=1&amp;md5=ae3ce0ad5d5858c3da72bc2f6d65d807\"><span class=\"bwuline\">www.merck.com<\/span>.<\/a>\n    <\/p>\n<p>\n      <b>About PAREXEL International<\/b>\n    <\/p>\n<p>\n      PAREXEL International Corporation is a leading global bio\/pharmaceutical<br \/>\n      services organization, providing a broad range of knowledge-based<br \/>\n      contract research, consulting, and medical communications services to<br \/>\n      the worldwide pharmaceutical, biotechnology and medical device<br \/>\n      industries. Committed to providing solutions that expedite<br \/>\n      time-to-market and peak-market penetration, PAREXEL has developed<br \/>\n      significant expertise across the development and commercialization<br \/>\n      continuum, from drug development and regulatory consulting to clinical<br \/>\n      pharmacology, clinical trials management, medical education and<br \/>\n      reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL,<br \/>\n      provides advanced technology solutions, including medical imaging, to<br \/>\n      facilitate the clinical development process. Headquartered near Boston,<br \/>\n      Massachusetts, PAREXEL operates in 71 locations throughout 54 countries<br \/>\n      around the world, and has approximately 10,170 employees. For more<br \/>\n      information about PAREXEL International visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.parexel.com%2F&amp;esheet=50281534&amp;lan=en-US&amp;anchor=www.PAREXEL.com.&amp;index=2&amp;md5=45fa3e284129d7b3e2b7eb9ab8abb2a3\"><span class=\"bwuline\">www.PAREXEL.com<\/span>.<\/a>\n    <\/p>\n<p>\n      This release contains \u201cforward-looking\u201d statements regarding future<br \/>\n      results and events, including, without limitation, statements regarding<br \/>\n      expected financial results, future growth and customer demand. For this<br \/>\n      purpose, any statements contained herein that are not statements of<br \/>\n      historical fact may be deemed forward-looking statements. Without<br \/>\n      limiting the foregoing, the words \u201cbelieves,\u201d \u201canticipates,\u201d \u201cplans,\u201d<br \/>\n      \u201cexpects,\u201d \u201cintends,\u201d \u201cappears,\u201d \u201cestimates,\u201d \u201cprojects,\u201d \u201cwill,\u201d<br \/>\n      \u201cwould,\u201d \u201ccould,\u201d \u201ctargets,\u201d and similar expressions are also intended<br \/>\n      to identify forward-looking statements. The forward-looking statements<br \/>\n      in this release involve a number of risks and uncertainties. The<br \/>\n      Company\u2019s actual future results may differ significantly from the<br \/>\n      results discussed in the forward-looking statements contained in this<br \/>\n      release. Important factors that might cause such a difference include,<br \/>\n      but are not limited to, risks associated with: actual operating<br \/>\n      performance; actual expense savings and other operating improvements<br \/>\n      resulting from recent and anticipated restructurings, the loss,<br \/>\n      modification, or delay of contracts which would, among other things,<br \/>\n      adversely impact the Company\u2019s recognition of revenue included in<br \/>\n      backlog; the Company\u2019s dependence on certain industries and clients; the<br \/>\n      Company\u2019s ability to win new business, manage growth and costs, and<br \/>\n      attract and retain employees; the Company\u2019s ability to complete<br \/>\n      additional acquisitions and to integrate newly acquired businesses or<br \/>\n      enter into new lines of business; the impact on the Company\u2019s business<br \/>\n      of government regulation of the drug, medical device and biotechnology<br \/>\n      industry; consolidation within the pharmaceutical industry and<br \/>\n      competition within the biopharmaceutical services industry; the<br \/>\n      potential for significant liability to clients and third parties; the<br \/>\n      potential adverse impact of health care reform; and the effects of<br \/>\n      exchange rate fluctuations and other international economic, political,<br \/>\n      and other risks. Such factors and others are discussed more fully in the<br \/>\n      section entitled \u201cRisk Factors\u201d of the Company\u2019s Quarterly Report on<br \/>\n      Form 10-Q for the quarter ended September 30, 2010 as filed with the SEC<br \/>\n      on November 9, 2010, which \u201cRisk Factors\u201d discussion is incorporated by<br \/>\n      reference in this press release. The Company specifically disclaims any<br \/>\n      obligation to update these forward-looking statements in the future.<br \/>\n      These forward-looking statements should not be relied upon as<br \/>\n      representing the Company\u2019s estimates or views as of any date subsequent<br \/>\n      to the date of this press release.\n    <\/p>\n<p>\n      PAREXEL is a registered trademark of PAREXEL International Corporation,<br \/>\n      and Perceptive Informatics is a trademark of Perceptive Informatics,<br \/>\n      Inc. All other names or marks may be registered trademarks or trademarks<br \/>\n      of PAREXEL International Corporation, Perceptive Informatics, Inc. or<br \/>\n      their respective owners and are hereby acknowledged.\n    <\/p>\n<p>\n      <b>Merck Forward Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes &#8220;forward-looking statements&#8221; within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. The forward-looking statements<br \/>\n      may include statements regarding product development, product potential,<br \/>\n      the company&#8217;s plans, objectives, expectations and intentions and other<br \/>\n      statements that are not historical facts. Such statements are based upon<br \/>\n      the current beliefs and expectations of Merck&#8217;s management and are<br \/>\n      subject to significant risks and uncertainties. Actual results may<br \/>\n      differ from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      The following factors, among others, could cause actual results to<br \/>\n      differ from those set forth in the forward-looking statements: the<br \/>\n      impact of pharmaceutical industry regulation and health care<br \/>\n      legislation; Merck&#8217;s ability to accurately predict future market<br \/>\n      conditions; dependence on the effectiveness of Merck&#8217;s patents and other<br \/>\n      protections for innovative products; the risk of new and changing<br \/>\n      regulation and health policies in the United States and internationally<br \/>\n      and the exposure to litigation and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck&#8217;s 2009 Annual Report on Form 10-K and the company&#8217;s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC&#8217;s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50281534&amp;lan=en-US&amp;anchor=www.sec.gov%29.&amp;index=3&amp;md5=af00c5c12e3a77f591490296214aa6a1\"><span class=\"bwuline\">www.sec.gov<\/span>).<\/a>\n    <\/p>\n<p>\n      Photos\/Multimedia Gallery Available: <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.businesswire.com%2Fcgi-bin%2Fmmg.cgi%3Feid%3D6570357%26lang%3Den&amp;esheet=50281534&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.businesswire.com%2Fcgi-bin%2Fmmg.cgi%3Feid%3D6570357%26lang%3Den&amp;index=4&amp;md5=2d2a31ea9aa9fc193f412a6a37cfa41f\"><span class=\"bwuline\">http:\/\/www.businesswire.com\/cgi-bin\/mmg.cgi?eid=6570357&amp;lang=en<\/span><\/a>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120517006576r1&amp;sid=sfsite1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Ian McConnell, 908-423-3046<br \/>Investors:<br \/>Joe        Romanelli, 908-423-5088<br \/>or<br \/>PAREXEL<br \/>Media:<br \/>Jennifer        Baird, 781-434-4409<br \/>Investors:<br \/>Jill Baker, 781-434-4118     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>PAREXEL to provide a broad range of regulatory and clinical services to Merck BioVentures including exclusivity for certain candidates Merck (NYSE:MRK) (known outside the United States and Canada as MSD) and PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that they have entered into an alliance by which PAREXEL will provide strategic access to global clinical development services for designated biosimilar candidates to Merck BioVentures. Merck BioVentures, a division of Merck, is focused on the delivery of high quality biosimilars to the patients that need them. &#8220;PAREXEL has extensive, industry-leading experience with biosimilar development, and we truly understand the scientific complexities, and regulatory pathways involved,&#8221; said Josef von Rickenbach, chairman and chief executive officer of PAREXEL. &#8220;We are committed to working with Merck BioVentures to assist in advancing its biosimilar portfolio in this<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,289],"class_list":["post-742146","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and PAREXEL Form Strategic Alliance Focused on Clinical Development of Biosimilar Candidates - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and PAREXEL Form Strategic Alliance Focused on Clinical Development of Biosimilar Candidates - Merck.com\" \/>\n<meta property=\"og:description\" content=\"PAREXEL to provide a broad range of regulatory and clinical services to Merck BioVentures including exclusivity for certain candidates Merck (NYSE:MRK) (known outside the United States and Canada as MSD) and PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that they have entered into an alliance by which PAREXEL will provide strategic access to global clinical development services for designated biosimilar candidates to Merck BioVentures. Merck BioVentures, a division of Merck, is focused on the delivery of high quality biosimilars to the patients that need them. &quot;PAREXEL has extensive, industry-leading experience with biosimilar development, and we truly understand the scientific complexities, and regulatory pathways involved,&quot; said Josef von Rickenbach, chairman and chief executive officer of PAREXEL. &quot;We are committed to working with Merck BioVentures to assist in advancing its biosimilar portfolio in this\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:19+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120517006576r1&amp;sid=sfsite1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\\\/\",\"name\":\"Merck and PAREXEL Form Strategic Alliance Focused on Clinical Development of Biosimilar Candidates - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120517006576r1&amp;sid=sfsite1&amp;distro=nx\",\"datePublished\":\"2011-01-12T07:30:00+00:00\",\"dateModified\":\"2026-08-10T17:01:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120517006576r1&amp;sid=sfsite1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20120517006576r1&amp;sid=sfsite1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and PAREXEL Form Strategic Alliance Focused on Clinical Development of Biosimilar Candidates\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and PAREXEL Form Strategic Alliance Focused on Clinical Development of Biosimilar Candidates - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\/","og_locale":"en_US","og_type":"article","og_title":"Merck and PAREXEL Form Strategic Alliance Focused on Clinical Development of Biosimilar Candidates - Merck.com","og_description":"PAREXEL to provide a broad range of regulatory and clinical services to Merck BioVentures including exclusivity for certain candidates Merck (NYSE:MRK) (known outside the United States and Canada as MSD) and PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced that they have entered into an alliance by which PAREXEL will provide strategic access to global clinical development services for designated biosimilar candidates to Merck BioVentures. Merck BioVentures, a division of Merck, is focused on the delivery of high quality biosimilars to the patients that need them. \"PAREXEL has extensive, industry-leading experience with biosimilar development, and we truly understand the scientific complexities, and regulatory pathways involved,\" said Josef von Rickenbach, chairman and chief executive officer of PAREXEL. \"We are committed to working with Merck BioVentures to assist in advancing its biosimilar portfolio in this","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:19+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120517006576r1&amp;sid=sfsite1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\/","name":"Merck and PAREXEL Form Strategic Alliance Focused on Clinical Development of Biosimilar Candidates - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120517006576r1&amp;sid=sfsite1&amp;distro=nx","datePublished":"2011-01-12T07:30:00+00:00","dateModified":"2026-08-10T17:01:19+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120517006576r1&amp;sid=sfsite1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20120517006576r1&amp;sid=sfsite1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-parexel-form-strategic-alliance-focused-on-clinical-development-of-biosimilar-candidates\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and PAREXEL Form Strategic Alliance Focused on Clinical Development of Biosimilar Candidates"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"320aa411-e788-4a6c-969c-d149cb838a68","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-and-PAREXEL-Form-Strategic-Alliance-Focused-on-Clinical-Development-of-Biosimilar-Candidates-2011.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742146","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742146\/revisions"}],"predecessor-version":[{"id":3679282,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742146\/revisions\/3679282"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742146"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742146"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}